{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:24:52Z","timestamp":1794857092667,"version":"4.9.1"},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,7,12]],"date-time":"2012-07-12T00:00:00Z","timestamp":1342051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:sec>\n                    <jats:title>What's known on the subject? and What does the study add?<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Phosphoesterase type 5 inhibitors (\n                            <jats:styled-content style=\"fixed-case\">PDE5is<\/jats:styled-content>\n                            ) are considered standard\u2010of\u2010care for the treatment of men with erectile dysfunction. Recommended administration of currently used\n                            <jats:styled-content style=\"fixed-case\">PDE5is<\/jats:styled-content>\n                            are between 60\u2010 to 120\u2010minutes before sexual activity. RigiScan\u00ae monitoring has been validated in previous clinical studies of\n                            <jats:styled-content style=\"fixed-case\">PDE5<\/jats:styled-content>\n                            inhibitors.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Using a highly objective measure of sexual function (RigiScan monitoring), data show that the onset of action of avanafil was rapid. Response to treatment with avanafil was associated most frequently with the earliest time interval tested (20\u201340 minutes after dosing), compared with sildenafil 50\u2009mg (100 to 120 minutes after dosing). However, avanafil treatments showed some degree of efficacy across all time intervals tested (including 60\u201380 minutes and 100\u2013120 minutes post\u2010dosing). These results were consistent with data from phase 3 trials which showed a rapid onset of action with avanafil (as early as 15 minutes) and a long duration of effect (up to 6 hours in some patients). Safety results were consistent with those reported in phase 3 trials, and showed that avanafil was well tolerated and adverse events were generally low and mild in severity.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            To evaluate the safety, efficacy and time course of three doses of avanafil (50\u2009mg, 100\u2009mg and 200\u2009mg) compared with sildenafil 50\u2009mg or placebo, given in conjunction with visual sexual stimulation (\n                            <jats:styled-content style=\"fixed-case\">VSS<\/jats:styled-content>\n                            ) videos in men with mild to moderate erectile dysfunction (\n                            <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                            ).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Male patients, 35\u201370 years of age, with mild to moderate\n                            <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                            of \u22656 months duration, were included in the study.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>During the course of the study, each patient received placebo, active control (sildenafil 50\u2009mg), and one dose of avanafil (50\u2009mg, 100\u2009mg or 200\u2009mg), all administered in random order at least 72\u2009h apart.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            RigiScan\u00ae (Dacomed Corp., Minneapolis,\n                            <jats:styled-content style=\"fixed-case\">MN<\/jats:styled-content>\n                            ,\n                            <jats:styled-content style=\"fixed-case\">USA<\/jats:styled-content>\n                            ) monitoring was used in conjunction with 20\u2010min\n                            <jats:styled-content style=\"fixed-case\">VSS<\/jats:styled-content>\n                            videos (20, 60, and 100\u2009min after dosing) to determine the duration of and time to \u226560% penile rigidity, maximum rigidity, tumescent activity units (\n                            <jats:styled-content style=\"fixed-case\">TAUs<\/jats:styled-content>\n                            ), rigidity activity units (\n                            <jats:styled-content style=\"fixed-case\">RAUs<\/jats:styled-content>\n                            ), and responses to the five\u2010point Erection Assessment Scale.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Safety assessments included adverse events (\n                            <jats:styled-content style=\"fixed-case\">AEs<\/jats:styled-content>\n                            ), vital sign changes in response to dosing, laboratory results (complete blood counts, chemistry panel, prostate\u2010specific antigen, serum testosterone, prothrombin time and urine analysis) and physical examination findings.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Eighty\u2010three patients were randomized and received at least one dose of study medication; 82 patients completed the study.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Peak response to avanafil occurred in the early interval (20\u201340\u2009min after dosing), while peak response to sildenafil occurred either in the middle (60\u201380\u2009min) or late (100\u2013120\u2009min) intervals after dosing.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Results were qualitatively similar for all other efficacy endpoints.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            During the 20\u201340\u2010min interval, the majority of values for\n                            <jats:styled-content style=\"fixed-case\">TAUs<\/jats:styled-content>\n                            and\n                            <jats:styled-content style=\"fixed-case\">RAUs<\/jats:styled-content>\n                            with the avanafil 50\u2010mg, 100\u2010mg and 200\u2010mg treatments were significantly superior to placebo (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.05).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Avanafil treatment was generally well tolerated; facial flushing (7\u201315%) was the most commonly observed\n                            <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                            , and no visual disturbances were reported.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            A favourable safety profile and improvement in sexual function, coupled with rapid onset of action and durability of effect, make avanafil an attractive option for males with\n                            <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                            , especially in the setting of on\u2010demand treatment.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11267.x","type":"journal-article","created":{"date-parts":[[2012,7,13]],"date-time":"2012-07-13T07:17:46Z","timestamp":1342163866000},"page":"137-147","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A phase\n                    <scp>II<\/scp>\n                    , single\u2010blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction"],"prefix":"10.1111","volume":"111","author":[{"given":"Wayne J.G.","family":"Hellstrom","sequence":"first","affiliation":[{"name":"Tulane University Medical Center  New Orleans LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Freier","sequence":"additional","affiliation":[{"name":"Tulane University Medical Center  New Orleans LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ege Can","family":"Serefoglu","sequence":"additional","affiliation":[{"name":"Tulane University Medical Center  New Orleans LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Georgia Health Sciences University  Augusta GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"DiDonato","sequence":"additional","affiliation":[{"name":"VIVUS, Inc  Mountain View CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Peterson","sequence":"additional","affiliation":[{"name":"VIVUS, Inc  Mountain View CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.06.010"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1999.00142.x"},{"key":"e_1_2_8_4_1","article-title":"The management of erectile dysfunction: an update","author":"Montague DK","year":"2007","journal-title":"Am Urol Assoc"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2011.02387.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901250"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02693.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.04.067"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.06.016"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000125198.32936.38"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67138-8"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.23.2996"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2009.01576.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901519"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.11.041"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2006.00286.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.06.049"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00614-2"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)34871-1"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67900-1"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.01778.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.02.020"},{"key":"e_1_2_8_23_1","volume-title":"Cialis (Package Insert)","author":"Eli Lilly and Company","year":"2011"},{"key":"e_1_2_8_24_1","volume-title":"Levitra (Package Insert)","author":"Bayer HealthCare Pharmaceuticals","year":"2011"},{"key":"e_1_2_8_25_1","volume-title":"Viagra (Package Insert)","author":"Pfizer Labs","year":"2010"},{"key":"e_1_2_8_26_1","volume-title":"STENDRA (Package Insert)","author":"VIVUS Inc","year":"2012"},{"key":"e_1_2_8_27_1","first-page":"S466","article-title":"Pharmacokinetics of avanafil, a novel, rapidly absorbed, selective PDE5 inhibitor for the treatment of mild to severe erectile dysfunction (ED)","volume":"8","author":"Allison M","year":"2011","journal-title":"J Sex Med"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.03.115"},{"key":"e_1_2_8_29_1","unstructured":"International Conference on Harmonisation.International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at:http:\/\/www.ich.org\/products\/guidelines.html. Accessed May2012"},{"key":"e_1_2_8_30_1","unstructured":"World Medical Association General Assembly.WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Subjects. Available at:http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/. Accessed May 2012"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2004.04026.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s003450000168"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.00034.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00841-4"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1996.10220.x"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805143382001"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)41709-5"},{"key":"e_1_2_8_38_1","first-page":"S396","article-title":"An open\u2010label, long\u2010term evaluation of the safety and tolerability of avanafil in males with erectile dysfunction","volume":"8","author":"Belkoff L","year":"2011","journal-title":"J Sex Med"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2011.02629.x"},{"key":"e_1_2_8_40_1","article-title":"Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double\u2010blind study in men with diabetes","author":"Goldstein I","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_8_41_1","first-page":"S42","article-title":"A phase III, placebo\u2010controlled study of the safety and efficacy of avanafil in the treatment of erectile dysfunction following bilateral, nerve\u2010sparing radical prostatectomy","volume":"9","author":"Mulhall JP","year":"2012","journal-title":"J Sex Med"},{"key":"e_1_2_8_42_1","doi-asserted-by":"crossref","unstructured":"HellstromJG FreierMT SerefogluECet\u2009al.Onset of action and time to efficacy of avanafil a novel rapid\u2010onset PDE5 inhibitor in men with mild to severe erectile dysfunction: data from phase 2 and phase 3 clinical trails presented at the American Urological Association (AUA) Annual Meeting; May 19\u201323 2012; Atlanta GA. Poster #MP\u201053","DOI":"10.1016\/j.juro.2012.02.2002"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1939-4640.2002.tb02332.x"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64442-4"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.04819.x"},{"key":"e_1_2_8_46_1","unstructured":"MulhallJP BurnettAL McVaryKTet\u2009al.Efficacy and safety of avanafil a next\u2010generation phosphodiesterase type 5 inhibitor for the treatment of men with erectile dysfunction: data from phase 2 and 3 studies in difficult\u2010to\u2010treat populations. Presented at the American Urological Association (AUA) Annual Meeting; May 19\u201323 2012; Atlanta GA. Oral presentation"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11267.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11267.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:21:58Z","timestamp":1761740518000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11267.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,12]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11267.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11267.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,12]]},"assertion":[{"value":"2012-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}